Literature DB >> 10971497

Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK.

J C Ravenscroft1, A Layton, M Barnham.   

Abstract

A retrospective study was carried out to investigate possible reasons for a marked increase in fusidic acid-resistant Staphylococcus aureus (FusR S. aureus) identified by our routine hospital microbiology service. Information was obtained on a sample of 64 consecutive patients from whom resistant S. aureus had been cultured. The source of isolates was found to be diffuse within the hospital and community. The site of sample was most frequently chronic cutaneous infections (68%). All the S. aureus isolates were resistant to both fusidic acid and penicillin and many were resistant to multiple antibiotics. Topical fusidic acid had been used by 40% of patients in the preceding 6 months and none had received oral fusidic acid (sodium fusidate). Most (80%) had received an oral antibiotic in the preceding 2 years. Information from the Prescriptions Pricing Authority revealed that the total number of prescriptions for fusidic acid-containing preparations for the period September 1997 to August 1998 was markedly higher in Harrogate than in five other local areas where increases in (FusR) S. aureus have not been observed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10971497     DOI: 10.1046/j.1365-2230.2000.00654.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  8 in total

1.  [Do sulfonamides still retain a place in dermatological therapy?].

Authors:  A Schnuch
Journal:  Hautarzt       Date:  2002-03       Impact factor: 0.751

2.  Fusidic acid cream for impetigo. Fusidic acid should be used with restraint.

Authors:  Erwin M Brown; Richard Wise
Journal:  BMJ       Date:  2002-06-08

Review 3.  Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns.

Authors:  Deborah A Williamson; Glen P Carter; Benjamin P Howden
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

4.  Oral and Topical Antibiotics for Clinically Infected Eczema in Children: A Pragmatic Randomized Controlled Trial in Ambulatory Care.

Authors:  Nick A Francis; Matthew J Ridd; Emma Thomas-Jones; Christopher C Butler; Kerenza Hood; Victoria Shepherd; Charis A Marwick; Chao Huang; Mirella Longo; Mandy Wootton; Frank Sullivan
Journal:  Ann Fam Med       Date:  2017-03       Impact factor: 5.166

5.  Interventions to reduce Staphylococcus aureus in the management of eczema.

Authors:  Susannah Mc George; Sanja Karanovic; David A Harrison; Anjna Rani; Andrew J Birnie; Fiona J Bath-Hextall; Jane C Ravenscroft; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-10-29

6.  A fusidic acid-resistant epidemic strain of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates.

Authors:  Alexander J O'Neill; Anders R Larsen; Anne S Henriksen; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Skin infections and antibiotic prescribing: a comparison of surveillance and prescribing data.

Authors:  Douglas M Fleming; Alex J Elliot; Helen Kendall
Journal:  Br J Gen Pract       Date:  2007-07       Impact factor: 5.386

8.  Antibiotic Susceptibility of Staphylococcus aureus in Atopic Dermatitis: Current Prevalence of Methicillin-Resistant Staphylococcus aureus in Korea and Treatment Strategies.

Authors:  Mi-Young Jung; Jong-Youn Chung; Hae-Young Lee; Jiho Park; Dong-Youn Lee; Jun-Mo Yang
Journal:  Ann Dermatol       Date:  2015-07-29       Impact factor: 1.444

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.